Terms & Conditions

BY USING THIS SITE YOU ACKNOWLEDGE THAT GENENTECH USA, INC. IS PROVIDING THE MATERIAL FOR INFORMATIONAL PURPOSES ONLY AND THAT NEITHER GENENTECH USA, INC. NOR THEIR LICENSORS ARE PROVIDING THE MATERIALS TO YOU FOR THE PURPOSES OF GIVING YOU MEDICAL ADVICE. YOU SHOULD NOT RELY ON THE MATERIALS IN DECIDING ON A TREATMENT PLAN, DRUG USAGE, OR ANY OTHER MEDICAL ADVICE REGARDING THE MATERIALS, AND GENENTECH USA, INC., AND THEIR LICENSORS STRONGLY URGE THAT YOU CONSULT WITH A PHYSICIAN IN CONNECTION WITH ANY AND ALL TREATMENT OPTIONS THAT MAY BE AVAILABLE TO YOU.

This site could contain technical inaccuracies and/or typographical errors. Genentech USA, Inc. may make improvements and/or changes in the materials contained on the site at any time.

IN NO EVENT SHALL GENENTECH USA, INC., ITS PARENT COMPANY OR EITHER OF THEIR LICENSORS BE LIABLE FOR ANY DIRECT, SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES OR ANY DAMAGES WHATSOEVER RESULTING FROM LOSS RELATED TO THE USE OF OUR WEBSITES, WHETHER IN AN ACTION OF CONTRACT, BREACH OF WARRANTY, NEGLIGENCE, OR OTHER TORTIOUS ACTION ARISING OUT OF OR IN CONNECTION WITH THE USE OF THE MATERIALS CONTAINED ON THIS SITE.
Tools & Resources

Get information on conferences, events, and how to order LUCENTIS and other materials for your patients.

LUCENTIS Resources 
LUCENTIS Access Solutions™

Helps resolve access and reimbursement issues for patients. Our specialists help patients gain access to LUCENTIS while supporting your practice throughout the reimbursement process.

Visit LUCENTIS Access Solutions 
LUCENTIS Direct

With LUCENTIS Direct, you can order LUCENTIS straight from Genentech. It’s friendly service and fast, overnight delivery.

Visit the website 
Call Us
Get more information on LUCENTIS at:
1.866.LUCENTIS
(1.866.582.3684)
Monday-Friday
9 AM-8 PM ET


INDICATION

LUCENTIS® (ranibizumab injection) is indicated for the treatment of patients with:
  • Neovascular (Wet) Age-Related Macular Degeneration (AMD)
  • Macular Edema Following Retinal Vein Occlusion (RVO)

IMPORTANT SAFETY INFORMATION

LUCENTIS is contraindicated in patients with ocular or periocular infections or hypersensitivity to ranibizumab or any of the excipients in LUCENTIS.

WARNINGS AND PRECAUTIONS
Intravitreal injections, including those with LUCENTIS, have been associated with endophthalmitis, retinal detachment, and iatrogenic traumatic cataract. Proper aseptic injection technique should always be utilized when administering LUCENTIS. Patients should be monitored during the week following the injection to permit early treatment, should an infection occur.

Increases in intraocular pressure (IOP) have been noted within 60 minutes of intravitreal injection. IOP and perfusion of the optic nerve head should be monitored and managed appropriately.

Although there was a low rate of arterial thromboembolic events (ATEs) observed in the LUCENTIS clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).

ADVERSE EVENTS
Serious adverse events related to the injection procedure occurring in <0.1% of intravitreal injections included endophthalmitis, rhegmatogenous retinal detachment, and iatrogenic traumatic cataract.

In neovascular (wet) age-related macular degeneration clinical trials, most common ocular side effects included conjunctival hemorrhage, eye pain, vitreous floaters, vitreous detachment, and intraocular inflammation. Most common non-ocular side effects included nasopharyngitis, headache, arthralgia, and bronchitis.

In macular edema following retinal vein occlusion clinical trials, most common ocular side effects included conjunctival hemorrhage, eye pain, and maculopathy. Most common non-ocular side effects included nasopharyngitis, headache, influenza, and sinusitis.

For additional safety information, please see LUCENTIS full prescribing information